COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cogent Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$30.01+0.49 (+1.66%)
Close on Oct 19, 2026
- Market cap
- $5.13B
- P/E (TTM)
- –
- Dividend yield
- –
Cogent Biosciences, Inc. revenue by segment
By business segment
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation Expense [Member] | -$741.00K | $626.00K | $628.00K | $641.00K | -$655.00K | $640.00K | $625.00K | $620.00K | $606.00K | $600.00K | +13.1% |
| Research and Development Software, Facilities and Other Strategic Support [Member] | -$6.54M | $5.73M | $5.89M | $5.01M | -$4.91M | $4.43M | -$390.00K | $4.15M | $3.84M | $3.22M | +33.2% |
| Early-stage, Preclinical and Discovery Programs [Member] | -$11.79M | $13.98M | $9.74M | $10.56M | -$10.04M | $9.78M | $8.43M | $7.63M | $5.56M | $6.52M | +17.5% |
| Stock-Based Compensation Expense [Member] | -$17.11M | $16.91M | $15.75M | $10.60M | -$9.72M | $10.01M | $9.98M | $10.36M | $10.01M | $9.39M | +76.1% |
| R&D Personnel Related [Member] | -$17.60M | $18.05M | $19.23M | $15.21M | -$14.57M | $14.87M | $13.80M | $11.72M | $10.84M | $10.68M | +20.8% |
| Other Operational Infrastructure and Advisory Support [Member] | -$23.27M | $20.22M | $15.63M | $9.11M | -$8.58M | $7.12M | $11.22M | $6.20M | $4.76M | $4.70M | +171.1% |
| Late-stage Development [Member] | -$25.59M | $28.10M | $32.62M | $32.23M | -$27.12M | $28.10M | $30.07M | $34.74M | $28.77M | $27.29M | -5.6% |
By product or service
By region
From the segment and revenue-disaggregation notes of Cogent Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.